There’s a new tool being used to combat the rise in COVID-19 cases brought on by the delta variant of the coronavirus: Regeneron. It’s the monoclonal antibody infusion therapy that can decrease chances of hospitalization by up to 70%.
“So once that happened, that’s when you saw Gov. Abbott and the national health officials and everybody really pushing for it,” she told the Standard.
But it took a while for Regeneron to gain traction this year because vaccinations were taking off.
“There was a lot of new information going on at the same time. And there was a whole lot of hesitancy early on by not only the public, but the medical community,” Harper said. “And there was a very, very slim set of guidelines for people who even qualified.”
But the qualifications for the drug therapy have changed.
“If you’re 12 and up, if you’ve been having symptoms for fewer than 10 days, is when it works the best,” she said.
A few months ago, 330,000 doses of Regeneron were sent to Texas. The therapy takes two hours to administer and it is free if prescribed.